Minimizing the Mess at Merck
The drugmaker needs a new CEO with a battle plan to craft a legal strategy for Vioxx, cut costs, and bolster new products
By Amy Barrett
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.